Cyclosporin A in combination with HAART in primary HIV-1 infection

HAART is the cornerstone of HIV therapy, and has significantly reduced morb idity and mortality associated with HIV disease. The institution of HAART d uring the primary HIV-1 infection has a more profound influence on the ulti mate pattern and rate of disease progression than therapy commenced later o n. However, it also well demonstrated that HAART alone is not able to eradi cate the virus, unless over a life-long period of time. There is therefore the need to develop alternative strategies aimed at modulating the immune r esponses in order to achieve the longterm control of HIV even once HAART is discontinued. Among immunomodulant agents, cyclosporin A in combination wi th HAART might play a role in the treatment of people with primary HIV-1 in fection.